| Name | Title | Contact Details |
|---|
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health.
Solutions for isolation, recovery, and analysis of intact, individual rare cells. Single "cell sorter"
Kyowa Pharmaceutical is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.